Bausch Health Companies Inc. — Form 8-K

Bausch Health reported Q2 2026 consolidated revenues of $2.85B (up 13% YoY; 11% organic), GAAP net income of $258M ($0.68 diluted EPS vs. $0.40 prior year), and adjusted EBITDA of $1.075B (up 28% YoY). The company raised full-year 2026 guidance for revenue ($10.79B–$11.04B, 4–6% growth), adjusted EBITDA ($4.05B–$4.175B, 8–11% growth), and adjusted operating cash flow ($1.4B–$1.475B). Bausch Health excluding Bausch + Lomb achieved 13 consecutive quarters of YoY revenue growth and raised guidance for full-year revenue ($5.35B–$5.50B, 4–6% growth) and adjusted EBITDA ($3.025B–$3.1B, 8–11% growth). Cash increased to $1.825B from $1.309B; no major counterparties or transactions named.